COMPUMEDICS RETURNS TO PROFITABILITY
Melbourne Australia, Thursday, 30 August, 2007 Leading Australian based medical diagnostics devices company, Compumedics Limited (ASX: CMP), is pleased to announce that it has returned to profitability in 2006-07 after two years of restructuring.
Compumedics Returns to Profitability
Melbourne Australia, Thursday, 30 August, 2007
Leading Australian based medical diagnostics devices company, Compumedics Limited (ASX: CMP), is pleased to announce that it has returned to profitability in 2006-07 after two years of restructuring.
Highlights and Achievements for the period
- Major turnaround in performance
- Sales stabilised despite adverse impact of unfavourable Forex movements
- Substantial reduction in operating costs
- Bank debt significantly reduced
- R&D pipeline maintained
- New breakout SomniLink® SPAP® technology released and first revenue generated
Profitable Trading Results for 30 June 2007
Compumedics achieved a net profit after tax in 2006-07 of $0.1 million compared with a loss of $1.6 million in the prior year. Revenue fell slightly to $36.7 million from $37.7 million largely due to adverse currency movements. All key financial metrics markedly improved in 2006-07 including:
- Gross margins were up from 52% to 59% despite currency movements
- Cash expenses were reduced by $2.8 million in 2006-07 and by $5 million over the past two years
- EBITDA in 2006-07 was $1.3 million compared with a loss of $0.5 million in 2005-06
- Operating cash flow recovered from a deficit of $1.5 million in 2005-06 to a positive $0.8 million
- Borrowings were substantially reduced from $6.4 million at June 2006 to $3.4 million as at June 2007
- Borrowing costs, however, jumped from $0.6 million in 2006 to $0.9 million in 2007
- Revenue growth achieved in USA (+11%), Europe (+16%), Australia (+5%) and DWL (+6%) offset by fall in Asia (-36%), the latter primarily being attributable to adverse temporary Chinese regulatory changes, and currency movements.
Concerted and targeted efforts since 2005 have resulted in a turnaround of the core business, which has returned to profitability after two years of losses.
Compumedics restructured its management team in 2005 and put in place systems to ensure costs were carefully controlled and monitored. These initiatives have resulted in an approximate $5 million reduction in operating costs notwithstanding a high priority to maintain research and development efforts.
Sales were stable despite the intense pressure from severe constraints imposed on working capital as the company successfully reduced its borrowings. Despite the marked reduction in borrowings, borrowing costs were very high. Nonetheless, these costs will be considerably lower in the current year.
In the face of these financial constraints, the Company maintained its R&D program and launched the SomniLink® SPAP®, an integrated positive airway-pressure system for the treatment of sleep apnoea. Further, the Company is about to release its innovative long-term neurological-monitoring product, Neuvo, which will take the business to another level.
David Burton, CEO, said about Compumedics’ results,
“The move to profitable trading in the core business is sustainable with the current revenue stream.”
“The restoration in profitability was achieved due to the focussed efforts of Compumedics’ dedicated and highly skilled team of employees on restructuring the Company to more cost-effectively deliver its world-class products.”
“I am pleased that, in the face of the constraints on working capital, the Compumedics team was able to maintain the level of revenue of recent years, with significantly reduced costs, and working capital. The Company is now in a stronger position to return to its traditional growth outlook, whilst restoring our cash reserves”
All divisions of the Group improve
Compumedics’ businesses include its core sleep-diagnostics products and consumables from its Sleep Division, Doppler ultrasound blood flow scanning products from its DWL Division, and brain function research and clinical neurology products from its Neuroscan Division. Each of these divisions demonstrated continued improvement over the past year, and despite the pressure on working capital each division maintained on-going research and development programs to supply a pipeline of new products.
Over the past year, Compumedics has complemented its robust direct-sales sleep-diagnostics business in Australia and the United States with a series of distribution agreements with partners in Europe and the Middle East, which should result in incremental revenue of at least $10 million over the next three years.
Compumedics will continue to pursue opportunities in each of the divisions of the group that will add profitable and sustainable growth and stand out growth where this is possible.
Affirmation of Compumedics’ Sleep-Treatment Strategy
Compumedics’ long-term strategy of complementing is suite of products for sleep diagnostics with new and innovative sleep treatment products reached a significant milestone in June 2007 with the completion of binding letter of intent with a major international partner in the medical devices market. The relationship commenced with Medigas Italia, a member of the global Praxair, Inc. group of companies, to commercialise Compumedics’ SomniLink® SPAP® system in Italy and eastern European countries. The sleep-treatment market is in the order of ten-fold greater in magnitude than the sleep-diagnostics market in which Compumedics’ current suite of products competes. Compumedics has commenced negotiations to exploit the greater global sleep-treatment market with several companies, collectively which represent $10 billion in annual sales. Compumedics expects to be able to update the market on outcomes of these negotiations when they reach material outcomes.
Outlook for 2007-08
Compumedics expects the business to grow overall in 2007-08 and for profitability to be enhanced through this growth and a continuing focus on costs and, in particular, financing costs.
Executive Chairman, CEO
For Further information:
Mr David Burton
Executive Chairman, CEO
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399
Investor Relations & Media Enquires:
Mr Rod North
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: +61 (0) 408 670 706
To view the Business Update presentation, click here. (PDF)
To view the announcement, click here. (PDF)